These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24039233)

  • 1. Intolerability of cobalt salt as erythropoietic agent.
    Ebert B; Jelkmann W
    Drug Test Anal; 2014 Mar; 6(3):185-9. PubMed ID: 24039233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cobalt chloride administration in athletes: a new perspective in blood doping?
    Lippi G; Franchini M; Guidi GC
    Br J Sports Med; 2005 Nov; 39(11):872-3. PubMed ID: 16244201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis.
    Beuck S; Schänzer W; Thevis M
    Drug Test Anal; 2012 Nov; 4(11):830-45. PubMed ID: 22362605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Biochim Biophys Acta; 2007 Sep; 1776(1):1-9. PubMed ID: 17683868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel erythropoiesis-stimulating agents: a new era in anemia management.
    Macdougall IC
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulating erythropoiesis: future perspectives.
    Mikhail A; Covic A; Goldsmith D
    Kidney Blood Press Res; 2008; 31(4):234-46. PubMed ID: 18587242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
    Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
    Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
    Tanaka T; Nangaku M
    Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating protein delivery in providing erythropoiesis and neuroprotection.
    Chang ZY; Chiang CH; Lu DW; Yeh MK
    Expert Opin Drug Deliv; 2008 Dec; 5(12):1313-21. PubMed ID: 19040394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of erythropoiesis-stimulating agents in human anti-doping control: past, present and future.
    Leuenberger N; Reichel C; Lasne F
    Bioanalysis; 2012 Jul; 4(13):1565-75. PubMed ID: 22831473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietic effects of low-dose cobalt application.
    Hoffmeister T; Schwenke D; Wachsmuth N; Krug O; Thevis M; Byrnes WC; Schmidt WFJ
    Drug Test Anal; 2019 Feb; 11(2):200-207. PubMed ID: 30110719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choice of erythropoiesis stimulating agent in ESRD.
    Fishbane S; Shah HH
    Nephrol News Issues; 2013 Jun; 27(7):Supp 10-2. PubMed ID: 23855143
    [No Abstract]   [Full Text] [Related]  

  • 16. Developments in the therapeutic use of erythropoiesis stimulating agents.
    Jelkmann W
    Br J Haematol; 2008 May; 141(3):287-97. PubMed ID: 18410567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin and erythropoiesis stimulating agents.
    Debeljak N; Sytkowski AJ
    Drug Test Anal; 2012 Nov; 4(11):805-12. PubMed ID: 22508651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).
    Krapf R; Hulter HN
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):470-80. PubMed ID: 19218474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoiesis-stimulating agents: development, detection and dangers.
    Franz SE
    Drug Test Anal; 2009 Jun; 1(6):245-9. PubMed ID: 20355203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.